NETest liquid biopsy is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease
We examined the utility of a neuroendocrine multigene transcript “liquid biopsy” (NETest) in bronchopulmonary carcinoids (BPC) for diagnosis and monitoring of disease status.
Aim: To independently validate the utility of the NETest in diagnosis and management of BPC in a multicenter, multinational blinded study.
Material and methods: The study cohorts assess ed were bronchopulmonary carcinoids (BPC) (n=99), healthy controls (n=102), other lung neoplasia (n=101) including adenocarcinomas (ACC) (n=41), squamous cell carcinomas (SCC) (n=37), SCLC (n=16) and LCNEC (n=7) and idiopathic pulmonary fibrosis (IPF) (n=50). BPC were histologically classified as TC (n=62) and AC (n=37). BPC disease status determination was based on imaging and RECIST 1.1. NETest diagnostic metrics and disease status accuracy were evaluated. Upper limit of normal (NETest) was 20. Twenty matched tissue-blood pairs were also evaluated. Data is mean± SD.
Results: NETest levels were significantly increased in BPC (45±25) vs controls (9±8, p
Source: Neuroendocrinology - Category: Endocrinology Source Type: research
More News: Adenocarcinoma | Brain | Cancer & Oncology | Carcinoma | Endocrinology | Neurology | Small Cell Lung Cancer | Squamous Cell Carcinoma | Study